Stem Cell Program, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Liver Transpl. 2011 Apr;17(4):418-27. doi: 10.1002/lt.22270.
The transplantation of primary hepatocytes has been shown to augment the function of damaged livers and to bridge patients to liver transplantation. However, primary hepatocytes often have low levels of engraftment and survive for only a short time after transplantation. To explore the potential benefits of using decellularized liver matrix (DLM) as a carrier for hepatocyte transplantation, DLM from whole mouse livers was generated. Human fetal hepatocytes immortalized by telomerase reconstitution (FH-hTERTs) or primary human hepatocytes were infused into the DLM, which was then implanted into the omenta of immunodeficient nonobese diabetic/severe combined immunodeficient/interleukin-2 receptor γ-deficient mice or nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis type VII mice. The removal of endogenous cellular components and the preservation of the extracellular matrix proteins and vasculature were demonstrated in the resulting DLM. Bioluminescent imaging revealed that FH-hTERTs transduced with a lentiviral vector expressing firefly luciferase survived in the DLM for 8 weeks after peritoneal implantation, whereas the luciferase signal from FH-hTERTs rapidly declined in control mice 3 to 4 weeks after transplantation via splenic injection or omental implantation after Matrigel encapsulation. Furthermore, primary human hepatocytes that were reconstituted in the DLM not only survived 6 weeks after transplantation but also maintained their function, as demonstrated by messenger RNA levels of albumin and cytochrome P450 (CYP) subtypes (CYP3A4, CYP2C9, and CYP1A1) similar to the levels in freshly isolated human primary hepatocytes (hPHs). In contrast, when hPHs were transplanted into mice via splenic injection, they failed to express CYP3A4, although they expressed albumin. In conclusion, DLM provides an excellent environment for long-term survival and maintenance of the hepatocyte phenotype after transplantation.
原代肝细胞移植已被证明可以增强受损肝脏的功能,并为肝移植患者提供过渡。然而,原代肝细胞通常植入水平较低,移植后仅能存活很短时间。为了探索使用去细胞化肝基质 (DLM) 作为肝细胞移植载体的潜在益处,从整个鼠肝中生成了 DLM。用人端粒酶重构永生化的胎肝细胞 (FH-hTERTs) 或原代人肝细胞被注入 DLM,然后将其植入免疫缺陷非肥胖型糖尿病/重症联合免疫缺陷/白细胞介素 2 受体 γ 缺陷小鼠或非肥胖型糖尿病/重症联合免疫缺陷/黏多糖贮积症 VII 型小鼠的大网膜中。结果表明,DLM 去除了内源性细胞成分,保留了细胞外基质蛋白和脉管系统。生物发光成像显示,用表达萤火虫荧光素酶的慢病毒载体转导的 FH-hTERTs 在腹腔内植入后 8 周仍能在 DLM 中存活,而未经转导的 FH-hTERTs 在对照组小鼠中,经脾内注射或 Matrigel 包封后的大网膜内植入后 3 至 4 周,荧光素酶信号迅速下降。此外,在 DLM 中重建的原代人肝细胞不仅在移植后 6 周内存活,而且其功能得以维持,其白蛋白和细胞色素 P450 (CYP) 亚型 (CYP3A4、CYP2C9 和 CYP1A1) 的信使 RNA 水平与新鲜分离的人原代肝细胞 (hPHs) 相似。相比之下,当 hPHs 经脾内注射移植到小鼠中时,尽管它们表达白蛋白,但未能表达 CYP3A4。总之,DLM 为移植后肝细胞长期存活和维持其表型提供了极佳的环境。